Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer
Authors:
- Phuoc T. TranPTPhuoc T. Tran
- Piet OstPOPiet Ost
- 1 November 2017
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 27 (6) , 587-595
Abstract
To summarize the available literature regarding radiotherapy as a metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (PCa). Three different clinical scenarios of oligometastatic PCa exist in which MDT can be applied: de novo oligometastatic PCa, oligorecurrent PCa, and oligoprogressive PCa. A cut off of three to five metastatic lesions is most often used in these settings. Data from retrospective studies, treating over 1000 patients in total, have been reported. The median progression-free survival ranges between 1 and 3 years, but is influenced by a heterogeneous use of androgen deprivation therapy. For lymph node metastases, a propensity scored matched analysis suggests that cancer specific and overall survival is improved with MDT over standard of care. MDT treatment regimens vary with different radiotherapy techniques, doses, and volumes. Adverse events are limited to grade 1–2 and only rarely grade 3 events are reported. Based on data from retrospective studies, progression-free survival following MDT for oligometastatic PCa is promising with few adverse events. Comparative prospective studies are under way and will shed light on the future of MDT.Keywords
This publication has 45 references indexed in Scilit:
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2014
- Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: Toxicity and matched case comparison with postoperative prostate bed-only radiotherapyRadiotherapy and Oncology, 2013
- Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapyAnnals of Oncology, 2013
- Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancerUrologic Oncology: Seminars and Original Investigations, 2013
- Choline PET or PET/CT and Biochemical Relapse of Prostate CancerClinical Nuclear Medicine, 2013
- Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastasesActa Oncologica, 2013
- Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancerFrontiers in Oncology, 2013
- Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodesRadiation Oncology, 2011